Patents by Inventor Kenneth Foreman

Kenneth Foreman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amino pyrimidine anticancer compounds
    Patent number: 9096624
    Abstract: Compounds of Formula 1, as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: August 4, 2015
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Andrew P. Crew, Dan Sherman, Rama Devi Appari, Xin Chen, Ramesh Chilukuri, Hanqing Dong, Caterina Ferraro, Kenneth Foreman, Ramesh C. Gupta, An-Hu Li, Kathryn M. Stolz, Brian Volk, Robert Zahler
  • 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Patent number: 8735405
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: May 27, 2014
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Lee D. Arnold, Cara Cesario, Heather Coate, Andrew P. Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark J. Mulvihill, Anthony I. Nigro, Bijoy Panicker, Arno G. Steinig, Yingchuan Sun, Quinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang
  • AMINO PYRIMIDINE ANTICANCER COMPOUNDS
    Publication number: 20130231306
    Abstract: Compounds of Formula 1, as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.
    Type: Application
    Filed: January 25, 2013
    Publication date: September 5, 2013
    Applicant: OSI Pharmaceuticals, LLC
    Inventors: Andrew P. CREW, Dan Sherman, Rama Devi Appari, Xin Chen, Ramesh Chilukuri, Hanqing Dong, Caterina Ferraro, Kenneth Foreman, Ramesh C. Gupta, An-Hu Li, Kathryn M. Stolz, Brian Volk, Robert Zahler
  • Amino pyrimidine anticancer compounds
    Patent number: 8399433
    Abstract: Compounds of Formula 1, as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: March 19, 2013
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Rama Devi Appari, Xin Chen, Ramesh Chilukuri, Andrew P. Crew, Hanqing Dong, Caterina Ferraro, Kenneth Foreman, Ramesh C. Gupta, An-Hu Li, Dan Sherman, Kathryn M. Stolz, Brian Volk, Robert Zahler
  • 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
    Publication number: 20120196847
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 2, 2012
    Inventors: Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Qingua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
    Publication number: 20120077979
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: December 1, 2011
    Publication date: March 29, 2012
    Inventors: Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Qingua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Patent number: 8101613
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: January 24, 2012
    Assignee: OSI Pharmaceuticals, LLC
    Inventors: Lee D. Arnold, Cara Cesario, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark J. Mulvihill, Anthony I. Nigro, Bijoy Panicker, Amo G. Steinig, Yingchuan Sun, Qinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang
  • AMINO PYRIMIDINE ANTICANCER COMPOUNDS
    Publication number: 20110136764
    Abstract: Compounds of Formula 1, as shown below and defined herein: and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by FAK.
    Type: Application
    Filed: June 1, 2010
    Publication date: June 9, 2011
    Applicant: OSI Pharmaceuticals, Inc.
    Inventors: Rama Devi APPARI, Xin CHEN, Ramesh Chllukuri, Andrew P. CREW, Hanqing DONG, Caterina FERRARO, Kenneth FOREMAN, Ramesh C. GUPTA, An-Hu LI, Dan SHERMAN, Kathryn M. STOLZ, Brian VOLK, Robert ZAHLER
  • 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Patent number: 7820662
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: October 26, 2010
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Lee D. Arnold, Cara Cesario, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark J. Mulvihill, Anthony I. Nigro, Bijoy Panicker, Arno G. Steinig, Yingchuan Sun, Quinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang
  • 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
    Publication number: 20090325928
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: August 12, 2009
    Publication date: December 31, 2009
    Inventors: Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Qingua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • Imidazopyrazine Tyrosine Kinase Inhibitors
    Publication number: 20090181940
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
    Type: Application
    Filed: July 18, 2008
    Publication date: July 16, 2009
    Inventors: Patricia Anne Beck, Cara Cesario, Matthew Cox, Han-Qing Dong, Kenneth Foreman, Mark Joseph Mulvihill, Anthony Innocenzo Nigro, Lydia Saroglou, Arno G. Steinig, Yingchuan Sun, Qinghua Weng, Douglas Werner, Wilkes Robin, Williams Jonathan
  • 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
    Publication number: 20090118499
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: October 3, 2008
    Publication date: May 7, 2009
    Inventors: Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Quinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • Imidazopyrazine tyrosine kinase inhibitors
    Patent number: 7459554
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
    Type: Grant
    Filed: October 14, 2004
    Date of Patent: December 2, 2008
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Han-Qing Dong, Kenneth Foreman, Mark Joseph Mulvihill, Anthony Innocenzo Nigro, Arno G. Steinig, Douglas Werner, Robin Wilkes
  • IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS
    Publication number: 20080227788
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
    Type: Application
    Filed: October 14, 2004
    Publication date: September 18, 2008
    Inventors: Patricia Beck, Cara Cesario, Matthew Cox, Han-Qing Dong, Kenneth Foreman, Mark Mulvihill, Anthony Nigro, Lydia Saroglou, Arno Steinig, Yingchuan Sun, Qinghua Weng, Douglas Werner, Robin Wilkes, Jonathan Williams
  • Pyrrolopyridine kinase inhibiting compounds
    Publication number: 20070129364
    Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least one of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Met, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    Type: Application
    Filed: December 5, 2006
    Publication date: June 7, 2007
    Inventors: Han-Qing Dong, Kenneth Foreman, An-Hu Li, Mark Mulvihill, Bijoy Panicker, Arno Steinig, Kathryn Stolz, Qinghua Weng, Meizhong Jin, Brian Volk, Jing Wang, Ti Wang, James Beard
  • 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors
    Publication number: 20060235031
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: March 31, 2005
    Publication date: October 19, 2006
    Inventors: Lee Arnold, Heather Coate, Andrew Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Mulvihill, Mark Mulvihill, Anthony Nigro, Bijoy Panicker, Arno Steinig, Qingua Weng, Douglas Werner, Michael Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
    Publication number: 20060211678
    Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    Type: Application
    Filed: August 1, 2005
    Publication date: September 21, 2006
    Inventors: Saleh Ahmed, Oscar Barba, Jason Bloxham, Graham Dawson, Wiliam Gattrell, John Kitchin, Neil Anthony Pegg, Imaad Saba, Shazia Sadiq, Colin Peter Sambrook Smith, Don Smyth, Amo Steing, Robin Wilkes, Bijoy Panicker, Paula Tavares, Matthew Cox, An-Hu Li, Hanqing Dong, Lifu Ma, Kenneth Foreman, Qinghua Weng, Kathryn Stolz
  • PTP1b inhibitors
    Publication number: 20060135488
    Abstract: This invention relates to modulating (e.g., inhibiting) protein tyrosine phosphatase 1B (PTP1B).
    Type: Application
    Filed: November 22, 2005
    Publication date: June 22, 2006
    Inventors: Jinbo Lee, Michael Smith, Alessandro Moretto, Zhao-Kui Wan, Eva Binnun, Weixin Xu, Kenneth Foreman, Diane Joseph-McCarthy, David Erbe, Steve Tam
  • Imidazopyrazine tyrosine kinase inhibitors
    Publication number: 20060084654
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein Q1 and R1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of various diseases and conditions that respond to treatment by inhibition of tyrosine kinases.
    Type: Application
    Filed: October 14, 2004
    Publication date: April 20, 2006
    Inventors: Patricia Beck, Cara Cesario, Matthew Cox, Han-Qing Dong, Kenneth Foreman, Mark Mulvihill, Anthony Nigro, Lydia Saroglou, Arno Steinig, Yingchuan Sun, Qinghua Weng, Douglas Werner, Robin Wilkes, Jonathan Williams
  • Inhibitors of protein tyrosine phosphatase 1B
    Publication number: 20050203087
    Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted thiophene compounds such as, for example, 2-carboxyl, 3-carboxymethoxy, 5-aryl substituted thiophenes, can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.
    Type: Application
    Filed: February 23, 2005
    Publication date: September 15, 2005
    Inventors: Jinbo Lee, Zhao-Kui Wan, Douglas Wilson, Bruce Follows, Steven Kirincich, Michael Smith, Jun-Jun Wu, Kenneth Foreman, David Erbe, Yan-Ling Zhang, Weixin Xu, Steve Tam